Evaluates pharmacokinetics and safety of IVL3003 in a novel injectable form, suggesting potential benefits over oral donepezil.
To evaluate the pharmacokinetics (PK), PD, and safety of IVL3003, a novel once-monthly long-acting injectable acetylcholinesterase inhibitor, compared with oral donepezil.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: